New drug duo tested to fight tough cancers
NCT ID NCT06130254
Summary
This early-phase trial is testing the safety and best dose of a combination of two targeted drugs, adagrasib and olaparib, for people with advanced solid tumors that have a specific genetic change called a KRAS G12C mutation. It will enroll about 52 adults with cancers like pancreatic, breast, gynecological, or certain lung cancers that have progressed after standard treatments. The main goal is to see if the drugs can be given together safely and to look for early signs that they might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.